In short
This article discusses a clinical trial investigating the long-term safety, tolerability, and effectiveness of ofatumumab in patients with relapsing multiple sclerosis (RMS). The study is an open-label, single-arm, multi-center extension trial that aims to evaluate the drug's performance over an extended period. While the main focus is on ofatumumab, the trial also includes information about a flu vaccine containing the B/Austria/1359417/2021-Like Strain (B/Singapore/Wuh4618/2021).
At a glance
- Study Type
- Open-label, single arm, multi-center extension study
- Main Objective
- Evaluate long-term safety and tolerability of ofatumumab in RMS patients
- Secondary Objectives
- Describe long-term efficacy, compare outcomes with immediate vs delayed treatment, explore health outcomes
- Key Inclusion Criteria
- Previous participation in Novartis MS study with ofatumumab, completed on study treatment
- Key Exclusion Criteria
- Premature discontinuation, >6 months since previous study, active infections, PML
- Primary Endpoints
- Adverse events, abnormal lab results, ECG findings, C-SSRS criteria
- Secondary Endpoints
- ARR, time to relapse, disability progression/improvement, MRI findings, NfL levels
- Treatment
- Ofatumumab 20 mg subcutaneous injection every 4 weeks
- Study Duration
- Through Week 240 (End of Study)
What is B/AUSTRIA/1359417/2021-LIKE STRAIN?
B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021) is a component of the influenza vaccine known as Flucelvax Tetra. This strain is a specific type of influenza B virus that has been selected for inclusion in the vaccine based on recommendations from health authorities. It is important to note that this strain is part of a vaccine and not a standalone medication.
Vaccine Composition
Flucelvax Tetra is a quadrivalent influenza vaccine, which means it contains four different strains of influenza virus. The vaccine includes:
- B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021)
- B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE)
- A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE)
- A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN (A/GEORGIA/12/2022 CVR-167)
These strains are carefully selected each year based on global surveillance of circulating influenza viruses to provide the best possible protection against seasonal flu.
Medical Use
Flucelvax Tetra, which contains the B/AUSTRIA/1359417/2021-LIKE STRAIN, is used to prevent influenza, commonly known as "the flu". Influenza is a highly contagious respiratory illness that can cause mild to severe symptoms and, in some cases, lead to hospitalization or even death, especially in high-risk groups.
The vaccine works by stimulating the body's immune system to produce antibodies against the included virus strains. This helps the body recognize and fight off these specific influenza viruses if exposed to them later.
Administration
Flucelvax Tetra is administered as an intramuscular injection. The vaccine comes in a pre-filled syringe containing a suspension for injection. The typical dose is 0.5 ml, which contains all four virus strains, including the B/AUSTRIA/1359417/2021-LIKE STRAIN.
It's important to note that this vaccine is typically given once per flu season. However, the exact dosing schedule may vary depending on factors such as age and previous flu vaccination history. Always follow the recommendations of your healthcare provider.
Safety and Effectiveness
The safety and effectiveness of influenza vaccines, including those containing the B/AUSTRIA/1359417/2021-LIKE STRAIN, are closely monitored by health authorities. These vaccines undergo rigorous testing before approval and continued surveillance after they are in use.
Like all vaccines, Flucelvax Tetra can cause side effects, although not everyone experiences them. Common side effects may include pain at the injection site, headache, fatigue, and muscle aches. These are usually mild and resolve on their own within a few days.
It's important to remember that the benefits of vaccination in preventing influenza and its complications generally outweigh the potential risks of side effects for most people. However, if you have concerns about the vaccine, you should discuss them with your healthcare provider.
In conclusion, the B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021) is an important component of the Flucelvax Tetra influenza vaccine, designed to provide protection against a specific strain of influenza B virus. As part of a quadrivalent vaccine, it contributes to broader protection against seasonal influenza.